ArticleThe Journal of veterinary medical science2020
Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer.
Article in The Journal of veterinary medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Prognostic Significance of the Tumour Microenvironment in Surgically Resected Canine Pulmonary Adenocarcinomas.Veterinary and comparative oncology · 2026Article
- Molecular Characterization of Hotspot Mutations in HER2, BRAF, KRAS, and PIK3CA in Canine Pulmonary Adenocarcinoma from Japan.Veterinary sciences · 2026Article
- Survival analysis of different treatment modalities and associated outcomes for canine primary pulmonary carcinoma.Frontiers in veterinary science · 2026Article
- Effects of trastuzumab emtansine on canine osteosarcoma cells.The Journal of veterinary medical science · 2025Article
- Unveiling HER2 immunoexpression in canine hepatoid gland neoplasms: clinicopathological and morphological associations.International journal of veterinary science and medicine · 2025Article
- Immunohistochemical characterization and potential prognostic relevance of dopamine signaling in canine pulmonary adenocarcinoma.Frontiers in veterinary science · 2025Article
- A single-cell RNA sequencing atlas of the healthy canine lung: a foundation for comparative studies.Frontiers in immunology · 2025Article
- Protein Expression, Amplification, and Mutation ofAnimals : an open access journal from MDPI · 2024Article
- Immunohistochemical Expression of Human Epidermal Growth Factor Receptor 2 and Ki67 in Apocrine Gland Anal Sac Adenocarcinoma.International journal of molecular sciences · 2024Article
- A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas.Animals : an open access journal from MDPI · 2024Article
- Anti-tumour effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines.Open veterinary journal · 2024Article
- Canine lung carcinoma-A descriptive review.Frontiers in veterinary science · 2024Review
- HER2 Overexpression and Cytogenetical Patterns in Canine Mammary Carcinomas.Veterinary sciences · 2022Article
- Gene expression of Nectin-4 and its clinical significance in dogs with primary lung adenocarcinoma.Veterinary medicine and science · 2022Article
- Immunohistochemical Screening of HER2 in Canine Carcinomas: A Preliminary Study.Animals : an open access journal from MDPI · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2) overexpression has been reported in various human cancers. HER2-targeted therapies showed clinical responses in humans with HER2-positive tumors. The incidence of canine primary lung cancer (cPLC) is increasing, but there are no effective systemic therapies for dogs with late-stage cPLC. HER2-targeted therapy could be an option for cPLC, but HER2 expression in cPLC remains unknown. We evaluated HER2 expression in cPLC. Immunohistochemical analysis revealed that 3 samples (19%) scored 3+; 8 (50%), 2+; 5 (31%); and 1+ and 0 (0%), 0. Of the cPLC tissues, 69% were HER2 positive (scored ≥2+). These data would lead to further evaluation of the role of HER2 in cPLC as a mechanism of malignancy and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.